(Q37445843)

20 August 2017

1 reference

title

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance (English)

1 reference

20 August 2017

0 references

1 reference

Lars L Gustafsson

6

0 references

Björn Wettermark

series ordinal

2

object named as

Björn Wettermark

1 reference

20 August 2017

1

Brian Godman

1 reference

20 August 2017

5

Alan Haycox

1 reference

20 August 2017

Mikael Hoffmann

3

1 reference

20 August 2017

Karolina Andersson

series ordinal

4

1 reference

20 August 2017

publication date

1 February 2009

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

65-83

1 reference

Swedish healthcare under pressure

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Enhancing the rational use of new medicines across European health care systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

How much will Herceptin really cost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Swedish registers to examine drug safety and clinical issues in RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Drug discovery: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Moving towards individualized medicine with pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Relationships between authors of clinical practice guidelines and the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Industry-sponsored clinical research: a broken system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Doctors' education: the invisible influence of drug company sponsorship

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Why did drug spending increase during the 1990s? A decomposition based on Swedish data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Pricing and reimbursement of drugs in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

From best evidence to best practice: effective implementation of change in patients' care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Janus computerised prescribing system provides pharmacological knowledge at point of care – design, development and proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Drug utilisation 90% profiles--a useful tool for quality assessment of prescribing in primary health care in Stockholm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Secondary prevention in a large stroke population: a study of patients' purchase of recommended drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

21 January 2018

Using clinical evidence

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Effluent from drug manufactures contains extremely high levels of pharmaceuticals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Balancing Big Pharma's books

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Pharmacotherapeutic circles. Results of an 18-month peer-review prescribing-improvement programme for general practitioners

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Impact of quality circles for improvement of asthma care: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Effects of a behaviour independent financial incentive on prescribing behaviour of general practitioners

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

How can we regulate medicines better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

Prescribing Incentive Schemes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.9.1.65

21 January 2018

Identifiers

DOI

10.1586/14737167.9.1.65

1 reference

20 August 2017

1 reference